Injectable extended-release naltrexone for opioid dependence: A double-blind, placebo-controlled, multicentre randomised trial

The Lancet

Volumn 377, Issue 9776, 2011, Pages 1506-1513

  Krupitsky, Evgeny ^a,e   Nunes, Edward V ^b   Ling, Walter ^c   Illeperuma, Ari ^d   Gastfriend, David R ^d   Silverman, Bernard L ^d  

^a PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Alkermes   (United States)

^e Bekhterev St Petersburg Psychoneurological Research Institute   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

DRUGS USED IN THE TREATMENT OF ADDICTION; EXTENDED RELEASE NALTREXONE; OPIATE; OPIATE ANTAGONIST; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL EVALUATION; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG DETOXIFICATION; DRUG RELEASE; DRUG TOLERABILITY; DRUG URINE LEVEL; ELECTROCARDIOGRAPHY; FEMALE; HEADACHE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INFLUENZA; INJECTION SITE; INJECTION SITE PAIN; INSOMNIA; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPIATE ADDICTION; OUTCOME ASSESSMENT; PATIENT COUNSELING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSYCHOSOCIAL REHABILITATION; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RUSSIAN FEDERATION; SAFETY; SAMPLE SIZE; SELF REPORT; SEROLOGY; TOOTH PAIN; TREATMENT RESPONSE; URINALYSIS; VISUAL ANALOG SCALE;

EID: 79955623045     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60358-9     Document Type: Article

References (35)

1. UNODC World Drug Report 2010 United Nations Publication New York, USA http://www.unodc.org/documents/wdr/WDR-2010/World-Drug-Report-2010-lo-res.pdf (accessed Oct 20, 2010).
2. Y Hser, MD Anglin, K Powers A 24-year follow-up of California narcotics addicts Arch Gen Psychiatry 50 1993 577 584 (Pubitemid 23203568)
3. HC Wilcox, KR Conner, ED Caine Association of alcohol and drug use disorders and completed suicide: an empirical review of cohort studies Drug Alcohol Depend 76S 2004 S11 S19
4. National Institute of Drug Abuse NIDA research report: heroin abuse and addiction http://www.unodc.org/documents/wdr/WDR-2010/World-Drug-Report-2010-lo- res.pdf 2005 (accessed March 24, 2011).
5. C Cook The global state of harm reduction 2010: key issues for broadening the response 2010 International Harm Reduction Association London http://www.ihra.net/files/2010/06/29/GlobalState2010-Web.pdf (accessed Nov 11, 2010).
6. B Mathers, L Degenhardt, H Ali for the 2009 Reference Group to the UN on HIV and Injecting Drug Use HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage Lancet 375 2010 1014 1028
7. JC Ball, A Ross The effectiveness of methadone maintenance treatment 1991 Springer-Verlag New York, NY, USA
8. RP Mattick, J Kimber, C Breen, M Davoli Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence Cochrane Database Syst Rev 2 2008 CD002207.
9. LA Marsch The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis Addiction 93 1988 515 532
10. H Kleber Pharmacologic treatments for opioid dependence: detoxification and maintenance options Dialogues Clin Neurosci 9 2007 455 470 (Pubitemid 351154632)
11. AT McLellan, JR McKay Components of successful addiction treatment AW Graham TK Schultz MF Mayo-Smith RK Ries BB Wilford Principles of addiction medicine 3rd edn. 2003 American Society of Addiction Medicine Chevy Chase, MD, USA 429 442
12. EV Nunes, JL Rothenberg, MA Sullivan, KM Carpenter, HD Kleber Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness? Am J Drug Alcohol Depend 32 2006 503 517 (Pubitemid 44870988)
13. S Minozzi, L Amato, S Vecchi, M Davoli, U Kirchmayer, A Verster Oral naltrexone maintenance treatment for opioid dependence Cochrane Database Syst Rev 1 2006 CD001333.
14. GK Hulse, N Morris, D Arnold-Reed Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone Arch Gen Psychiatry 66 2009 1108 1115
15. N Kunøe, P Lobmaier, JK Vederhus Naltrexone implants after in-patient treatment for opioid dependence: randomized controlled trial Br J Psychiatry 194 2009 541 546
16. SD Comer, MA Sullivan, E Yu Injectable, sustained-release naltrexone for the treatment of opioid dependence Arch Gen Psychiatry 63 2006 210 218
17. JC Garbutt, HR Kranzler, SS O'Malley Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial JAMA 293 2005 1617 1625 (Pubitemid 40471792)
18. SS O'Malley, JC Garbutt, DR Gastfriend, Q Dong, HR Kranzler Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment J Clin Psychopharmacol 27 2007 507 512 (Pubitemid 47415052)
19. DR Gastfriend Intramuscular extended-release naltrexone: current evidence Ann NY Acad Sci 1216 2011 144 166
20. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 4th edn, text revision (DSM-IV-TR) 2000 American Psychiatric Association Washington, DC
21. DE Mercer, GE Woody Therapy manuals for drug addiction series. Individual Drug Counseling 1999 National Institutes of Health, US Department of Health and Human Services Rockville, MD
22. LC Sobell, MB Sobell Timeline follow-back: a technique for assessing self-reported alcohol consumption RZ Litten JP Allen Measuring alcohol consumption: psychosocial and biological methods 1992 The Humana Press Totowa, NJ 41 72
23. EM Krupitsky, EE Zvartau, DV Masalov Naltrexone for heroin dependence treatment in St. Petersburg, Russia J Subst Abuse Treat 26 2004 285 294 (Pubitemid 38759145)
24. DS Metzger, HA Navaline, GE Woody Assessment of substance abuse: HIV risk assessment battery (RAB) R Carson-DeWitt G Macmillan-Thomson Encyclopedia of drugs, alcohol, and addictive behavior 2001 Macmillan Reference New York
25. JE Ware, M Kosinski, JE Dewey How to score version two of the SF-36 Health Survey 2000 QualityMetric Lincoln, RI
26. Euroqol Group Euroqol - a new facility for the measurement of health-related quality of life Health Policy 16 1990 199 208
27. W Guy ECDEU Assessment for psychopharmacology revised edition 1976 NIMH Publications Rockville, MD, USA
28. BL van der Waerden Order tests for the two-sample problem. II, III Proc K Ned Akad Wet A 564 1953 303 316
29. S Holm A simple sequentially rejective multiple test procedure Scand J Statist 6 1979 65 70
30. VN Amirdjanova, DV Goryachev, NI Korshunov, AP Rebrov, VN Sorotskaya Population indices of quality of life on SF-36: results of the multicentral study of quality of life "MIRAZH" Rheumatol Sci Pract 1 2008 36 48
31. BA Dijkstra, CA De Jong, SM Bluschke, PF Krabbe, CP van der Staak Does naltrexone affect craving in abstinent opioid-dependent patients? Addict Biol 12 2007 176 182 (Pubitemid 46753651)
32. JL Dunbar, RZ Turncliff, Q Dong, BL Silverman, EW Ehrich, KC Lasseter Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone Alcohol Clin Exp Res 30 2006 480 490 (Pubitemid 43341354)
33. RL Dean, MS Todtenkopf, DR Deaver Overriding the blockade of antinociceptive actions of opioids in rats treated with extended-release naltrexone Pharmacol Biochem Behav 89 2008 515 522
34. The Paris Pact Initiative Illicit drug trends in the Russian Federation. United Nations Office on Drugs and Crime Regional Office for Central Asia. Moscow http://www.unodc.org/documents/regional/central-asia/ Illicit20Drug20Trends20Report-Russia.pdf April 2008 (accessed April 25, 2010).
35. P Lobmaier, M Gossop, H Waal, J Bramness The pharmacological treatment of opioid addiction - a clinical perspective Eur J Clin Pharmacol 66 2010 537 545